Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02738866 · ClinicalTrials.gov registry record · Phase 2
Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor
A Phase 2 study of Metastatic Breast Cancer, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Active
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 5
- Study locations
NCT02738866: Active Phase 2 study of Metastatic Breast Cancer, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
NCT02738866 is a Phase 2 study of Metastatic Breast Cancer that is active but no longer recruiting, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 60 participants, below the 205-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (71% lower). The trial reports 5 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02738866, a Phase 2 study of Metastatic Breast Cancer, is active but no longer recruiting, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 5
- Study locations
Study Summary
This study is being done to look at the role of continuing palbociclib treatment in combination with another type of hormonal therapy (fulvestrant) after disease progression of palbociclib in combination with an aromatase inhibitor.
Primary Outcome
To estimate progression-free survival (PFS) of palbociclib and fulvestrant in women and men with ER/PR-positive, HER2-negative MBC who progressed on a palbociclib and an AI
Conditions Studied
Interventions
- DRUG Fulvestrant
- DRUG Palbociclib
Study Locations (5)
Maryland
- Anne Arundel Health System Research Institute, Inc. - Annapolis
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins - Baltimore
Pennsylvania
- Allegheny Health Network (AHN) - Allegheny General Hospital ONLY - Pittsburgh
- Reading Hospital - McGlinn Cancer Institute - West Reading
District of Columbia
- Kimmel Cancer Center at Johns Hopkins at Sibley Memorial Hospital - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2016-10-25 |
| Est. Completion | 2026-06 |
| Phase | Phase 2 |
What the registry record for NCT02738866 still lists
NCT02738866 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 205-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (71% lower).
The record links to 1 condition, with Metastatic Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Fulvestrant is the first listed.
NCT02738866 lists 5 locations in 3 states (Maryland, Pennsylvania, District of Columbia).
Frequently Asked Questions
What is clinical trial NCT02738866 about?
NCT02738866 is a clinical study titled "Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor". This study is being done to look at the role of continuing palbociclib treatment in combination with another type of hormonal therapy (fulvestrant) after disease progression of palbociclib in combination with an aromatase inhibitor.
What is the current status of trial NCT02738866?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2016-10-25. Estimated completion is 2026-06.
What conditions does trial NCT02738866 study?
This clinical trial studies the following conditions: Metastatic Breast Cancer.
What interventions are being tested in trial NCT02738866?
The interventions under investigation include: Fulvestrant (DRUG), Palbociclib (DRUG).
Who is sponsoring clinical trial NCT02738866?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02738866 being conducted?
This trial has 5 study locations across District of Columbia, Maryland, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02738866's enrollment target sits among peer trials
60 79th of 139 higher than 61 of 139 other Metastatic Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Nurturing Exercise Routine for Greater Improvement in Zest and Energy on Enhertu
RECRUITING · Phase 2
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer
RECRUITING · Phase 2
-
A Study of Surgery and Radiotherapy in People With Breast Cancer
RECRUITING · Phase 2
-
A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer
RECRUITING · Phase 2
-
A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI